Global Smallpox Vaccine Market
Global Smallpox Vaccine Market

Smallpox Vaccine Comprehensive Study by Type (First Generation, Second Generation, Third Generation), Application (Vaccination) Players and Region - Global Market Outlook to 2024

Smallpox Vaccine Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2019 Edition 203 Pages 163 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Market Snapshot:
Smallpox virus was eradicated from the world and the process of routine vaccination was stopped but the exposure of people working with the virus in the laboratory is still a big concern. Smallpox vaccine is made from vaccinia virus and belongs to Orthopoxvirus. The virus is a live virus so vaccinated people take extra precautions from virus to spread. Some of the side effects of the smallpox vaccine may lead to severe disability, permanent nerve damage, and or death.

Market Trend
Vaccine-preventable diseases such as Smallpox have lost their threat due to the introduction of the vaccines and global eradication of vaccines, people around the world including those in richer countries are benefitting from vaccinations.

Market Drivers
High prevalence of Infectious diseases, Increasing support for Vaccine R&D by government agencies like WHO (World Health Organizations), High Investments into vaccine development and Rising focus on immunization programmes.

Opportunities
The low price of smallpox vaccines compared with other health interventions has made them especially attractive as a way to improve global health.

The Players Covered in the Study are:
Bavarian Nordic (Denmark), Sanofi Pasteur Biologics LLC. (United States), Emergent BioSolutions Inc. (United States) and Wyeth Laboratories, Inc. (United States)


Report Objectives / Segmentation Covered
By Type
  • First Generation
  • Second Generation
  • Third Generation
By Application
  • Vaccination
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High prevalence of Infectious diseases
      • 3.2.2. Increasing support for Vaccine R&D by government agencies like WHO (World Health Organizations)
      • 3.2.3. High Investments into vaccine development
      • 3.2.4. Rising focus on immunization programmes.
    • 3.3. Market Challenges
      • 3.3.1. High-cost Investments for vaccine development.
    • 3.4. Market Trends
      • 3.4.1. Vaccine-preventable diseases such as Smallpox have lost their threat due to the introduction of the vaccines and global eradication of vaccines, people around the world including those in richer countries are benefitting from vaccinations.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Smallpox Vaccine, by Type, Application and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Smallpox Vaccine (Value)
      • 5.2.1. Global Smallpox Vaccine by: Type (Value)
        • 5.2.1.1. First Generation
        • 5.2.1.2. Second Generation
        • 5.2.1.3. Third Generation
      • 5.2.2. Global Smallpox Vaccine by: Application (Value)
        • 5.2.2.1. Vaccination
      • 5.2.3. Global Smallpox Vaccine Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Smallpox Vaccine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bavarian Nordic (Denmark)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi Pasteur Biologics LLC. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Emergent BioSolutions Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Wyeth Laboratories, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
  • 7. Global Smallpox Vaccine Sale, by Type, Application and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Smallpox Vaccine (Value)
      • 7.2.1. Global Smallpox Vaccine by: Type (Value)
        • 7.2.1.1. First Generation
        • 7.2.1.2. Second Generation
        • 7.2.1.3. Third Generation
      • 7.2.2. Global Smallpox Vaccine by: Application (Value)
        • 7.2.2.1. Vaccination
      • 7.2.3. Global Smallpox Vaccine Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Smallpox Vaccine: by Type(USD Million)
  • Table 2. Smallpox Vaccine First Generation , by Region USD Million (2013-2018)
  • Table 3. Smallpox Vaccine Second Generation , by Region USD Million (2013-2018)
  • Table 4. Smallpox Vaccine Third Generation , by Region USD Million (2013-2018)
  • Table 5. Smallpox Vaccine: by Application(USD Million)
  • Table 6. Smallpox Vaccine Vaccination , by Region USD Million (2013-2018)
  • Table 7. South America Smallpox Vaccine, by Country USD Million (2013-2018)
  • Table 8. South America Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 9. South America Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 10. Brazil Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 11. Brazil Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 12. Argentina Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 13. Argentina Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 14. Rest of South America Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 15. Rest of South America Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 16. Asia Pacific Smallpox Vaccine, by Country USD Million (2013-2018)
  • Table 17. Asia Pacific Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 18. Asia Pacific Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 19. China Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 20. China Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 21. Japan Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 22. Japan Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 23. India Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 24. India Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 25. South Korea Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 26. South Korea Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 27. Taiwan Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 28. Taiwan Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 29. Australia Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 30. Australia Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 31. Rest of Asia-Pacific Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 32. Rest of Asia-Pacific Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 33. Europe Smallpox Vaccine, by Country USD Million (2013-2018)
  • Table 34. Europe Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 35. Europe Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 36. Germany Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 37. Germany Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 38. France Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 39. France Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 40. Italy Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 41. Italy Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 42. United Kingdom Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 43. United Kingdom Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 44. Rest of Europe Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 45. Rest of Europe Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 46. MEA Smallpox Vaccine, by Country USD Million (2013-2018)
  • Table 47. MEA Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 48. MEA Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 49. Middle East Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 50. Middle East Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 51. Africa Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 52. Africa Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 53. North America Smallpox Vaccine, by Country USD Million (2013-2018)
  • Table 54. North America Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 55. North America Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 56. United States Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 57. United States Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 58. Canada Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 59. Canada Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 60. Mexico Smallpox Vaccine, by Type USD Million (2013-2018)
  • Table 61. Mexico Smallpox Vaccine, by Application USD Million (2013-2018)
  • Table 62. Company Basic Information, Sales Area and Its Competitors
  • Table 63. Company Basic Information, Sales Area and Its Competitors
  • Table 64. Company Basic Information, Sales Area and Its Competitors
  • Table 65. Company Basic Information, Sales Area and Its Competitors
  • Table 66. Smallpox Vaccine: by Type(USD Million)
  • Table 67. Smallpox Vaccine First Generation , by Region USD Million (2019-2024)
  • Table 68. Smallpox Vaccine Second Generation , by Region USD Million (2019-2024)
  • Table 69. Smallpox Vaccine Third Generation , by Region USD Million (2019-2024)
  • Table 70. Smallpox Vaccine: by Application(USD Million)
  • Table 71. Smallpox Vaccine Vaccination , by Region USD Million (2019-2024)
  • Table 72. South America Smallpox Vaccine, by Country USD Million (2019-2024)
  • Table 73. South America Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 74. South America Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 75. Brazil Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 76. Brazil Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 77. Argentina Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 78. Argentina Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 79. Rest of South America Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 80. Rest of South America Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 81. Asia Pacific Smallpox Vaccine, by Country USD Million (2019-2024)
  • Table 82. Asia Pacific Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 83. Asia Pacific Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 84. China Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 85. China Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 86. Japan Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 87. Japan Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 88. India Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 89. India Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 90. South Korea Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 91. South Korea Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 92. Taiwan Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 93. Taiwan Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 94. Australia Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 95. Australia Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 96. Rest of Asia-Pacific Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 97. Rest of Asia-Pacific Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 98. Europe Smallpox Vaccine, by Country USD Million (2019-2024)
  • Table 99. Europe Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 100. Europe Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 101. Germany Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 102. Germany Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 103. France Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 104. France Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 105. Italy Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 106. Italy Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 107. United Kingdom Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 108. United Kingdom Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 109. Rest of Europe Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 110. Rest of Europe Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 111. MEA Smallpox Vaccine, by Country USD Million (2019-2024)
  • Table 112. MEA Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 113. MEA Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 114. Middle East Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 115. Middle East Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 116. Africa Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 117. Africa Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 118. North America Smallpox Vaccine, by Country USD Million (2019-2024)
  • Table 119. North America Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 120. North America Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 121. United States Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 122. United States Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 123. Canada Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 124. Canada Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 125. Mexico Smallpox Vaccine, by Type USD Million (2019-2024)
  • Table 126. Mexico Smallpox Vaccine, by Application USD Million (2019-2024)
  • Table 127. Research Programs/Design for This Report
  • Table 128. Key Data Information from Secondary Sources
  • Table 129. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Smallpox Vaccine: by Type USD Million (2013-2018)
  • Figure 5. Global Smallpox Vaccine: by Application USD Million (2013-2018)
  • Figure 6. South America Smallpox Vaccine Share (%), by Country
  • Figure 7. Asia Pacific Smallpox Vaccine Share (%), by Country
  • Figure 8. Europe Smallpox Vaccine Share (%), by Country
  • Figure 9. MEA Smallpox Vaccine Share (%), by Country
  • Figure 10. North America Smallpox Vaccine Share (%), by Country
  • Figure 11. Global Smallpox Vaccine share by Players 2018 (%)
  • Figure 12. BCG Matrix for key Companies
  • Figure 13. Bavarian Nordic (Denmark) Revenue, Net Income and Gross profit
  • Figure 14. Bavarian Nordic (Denmark) Revenue: by Geography 2018
  • Figure 15. Sanofi Pasteur Biologics LLC. (United States) Revenue, Net Income and Gross profit
  • Figure 16. Sanofi Pasteur Biologics LLC. (United States) Revenue: by Geography 2018
  • Figure 17. Emergent BioSolutions Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Emergent BioSolutions Inc. (United States) Revenue: by Geography 2018
  • Figure 19. Wyeth Laboratories, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Wyeth Laboratories, Inc. (United States) Revenue: by Geography 2018
  • Figure 21. Global Smallpox Vaccine: by Type USD Million (2013-2018)
  • Figure 22. Global Smallpox Vaccine: by Application USD Million (2013-2018)
  • Figure 23. South America Smallpox Vaccine Share (%), by Country
  • Figure 24. Asia Pacific Smallpox Vaccine Share (%), by Country
  • Figure 25. Europe Smallpox Vaccine Share (%), by Country
  • Figure 26. MEA Smallpox Vaccine Share (%), by Country
  • Figure 27. North America Smallpox Vaccine Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Bavarian Nordic (Denmark)
  • Sanofi Pasteur Biologics LLC. (United States)
  • Emergent BioSolutions Inc. (United States)
  • Wyeth Laboratories, Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation